Role of Anti-Müllerian Hormone in Pathophysiology, Diagnosis and Treatment of Polycystic Ovary Syndrome: a Review

Overview

Journal Reprod Biol Endocrinol

Publisher Biomed Central

Specialties Endocrinology
Reproductive Medicine

Date 2015 Dec 23

PMID 26691645

Citations 55

Authors

Agathe Dumont

Geoffroy Robin

Sophie Catteau-Jonard

Didier Dewailly

Affiliations

Soon will be listed here.

Abstract

Polycystic ovary syndrome (PCOS) is the most common cause of chronic anovulation and hyperandrogenism in young women. Excessive ovarian production of Anti-Müllerian Hormone, secreted by growing follicles in excess, is now considered as an important feature of PCOS. The aim of this review is first to update the current knowledge about the role of AMH in the pathophysiology of PCOS. Then, this review will discuss the improvement that serum AMH assay brings in the diagnosis of PCOS. Last, this review will explain the utility of serum AMH assay in the management of infertility in women with PCOS and its utility as a marker of treatment efficiency on PCOS symptoms. It must be emphasized however that the lack of an international standard for the serum AMH assay, mainly because of technical issues, makes it difficult to define consensual thresholds, and thus impairs the widespread use of this new ovarian marker. Hopefully, this should soon improve.

Citing Articles

Perspectives on biomarkers of reproductive aging for fertility and beyond.

Wang S, Ren J, Jing Y, Qu J, Liu G Nat Aging. 2024; 4(12):1697-1710.

PMID: 39672897 DOI: 10.1038/s43587-024-00770-5.

Clinical utility of anti-Müllerian hormone in female children and adolescents.

Birbas E, Vatopoulou A, Kanavos T, Birmpas K, Skentou C, Zikopoulos A Hormones (Athens). 2024; .

PMID: 39477856 DOI: 10.1007/s42000-024-00603-5.

Anti-Müllerian hormone a surrogate of follicular fluid oxidative stress in polycystic ovary syndrome?.

Vale-Fernandes E, Moreira M, Rodrigues B, Pereira S, Leal C, Barreiro M Front Cell Dev Biol. 2024; 12:1408879.

PMID: 39011395 PMC: 11246868. DOI: 10.3389/fcell.2024.1408879.

Alternative treatment of polycystic ovary syndrome: pre-clinical and clinical basis for using plant-based drugs.

Malik S, Saeed S, Saleem A, Khan M, Khan A, Akhtar M Front Endocrinol (Lausanne). 2024; 14:1294406.

PMID: 38725974 PMC: 11081130. DOI: 10.3389/fendo.2023.1294406.

Effect of metformin on anti-mullerian hormone levels in women with polycystic ovarian syndrome: a systematic review and meta-regression analysis of randomized controlled trials with.

Mehdinezhad Roshan M, Sohouli M, Magalhaes E, Hekmatdoost A BMC Endocr Disord. 2024; 24(1):43.

PMID: 38549135 PMC: 10979616. DOI: 10.1186/s12902-024-01570-z.

References

Nachtigal M, Ingraham H . Bioactivation of Müllerian inhibiting substance during gonadal development by a kex2/subtilisin-like endoprotease. Proc Natl Acad Sci U S A. 1996; 93(15):7711-6. PMC: 38812. DOI: 10.1073/pnas.93.15.7711. View

Willis D, Watson H, Mason H, Galea R, Brincat M, Franks S . Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation. J Clin Endocrinol Metab. 1998; 83(11):3984-91. DOI: 10.1210/jcem.83.11.5232. View

van Rooij I, Broekmans F, Te Velde E, Fauser B, Bancsi L, de Jong F . Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Hum Reprod. 2002; 17(12):3065-71. DOI: 10.1093/humrep/17.12.3065. View

Fanchin R, Schonauer L, Righini C, Guibourdenche J, Frydman R, Taieb J . Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod. 2003; 18(2):323-7. DOI: 10.1093/humrep/deg042. View

Webber L, Stubbs S, Stark J, Trew G, Margara R, Hardy K . Formation and early development of follicles in the polycystic ovary. Lancet. 2003; 362(9389):1017-21. DOI: 10.1016/s0140-6736(03)14410-8. View

Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S . Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003; 88(12):5957-62. DOI: 10.1210/jc.2003-030727. View

Azziz R, Marin C, Hoq L, Badamgarav E, Song P . Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab. 2005; 90(8):4650-8. DOI: 10.1210/jc.2005-0628. View

Hehenkamp W, Looman C, Themmen A, de Jong F, Te Velde E, Broekmans F . Anti-Müllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab. 2006; 91(10):4057-63. DOI: 10.1210/jc.2006-0331. View

Durlinger A, Kramer P, Karels B, de Jong F, Uilenbroek J, Grootegoed J . Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary. Endocrinology. 1999; 140(12):5789-96. DOI: 10.1210/endo.140.12.7204. View

10.

Jakimiuk A, Weitsman S, NAVAB A, Magoffin D . Luteinizing hormone receptor, steroidogenesis acute regulatory protein, and steroidogenic enzyme messenger ribonucleic acids are overexpressed in thecal and granulosa cells from polycystic ovaries. J Clin Endocrinol Metab. 2001; 86(3):1318-23. DOI: 10.1210/jcem.86.3.7318. View

11.

Balen A, Laven J, Tan S, Dewailly D . Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update. 2004; 9(6):505-14. DOI: 10.1093/humupd/dmg044. View

12.

Laven J, Mulders A, Visser J, Themmen A, de Jong F, Fauser B . Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab. 2004; 89(1):318-23. DOI: 10.1210/jc.2003-030932. View

13.

Salmon N, Handyside A, Joyce I . Oocyte regulation of anti-Müllerian hormone expression in granulosa cells during ovarian follicle development in mice. Dev Biol. 2004; 266(1):201-8. DOI: 10.1016/j.ydbio.2003.10.009. View

14.

Weenen C, Laven J, von Bergh A, Cranfield M, Groome N, Visser J . Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004; 10(2):77-83. DOI: 10.1093/molehr/gah015. View

15.

Jonard S, Dewailly D . The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update. 2004; 10(2):107-17. DOI: 10.1093/humupd/dmh010. View

16.

HUGHESDON P . Morphology and morphogenesis of the Stein-Leventhal ovary and of so-called "hyperthecosis". Obstet Gynecol Surv. 1982; 37(2):59-77. DOI: 10.1097/00006254-198202000-00001. View

17.

Dunaif A, Segal K, FUTTERWEIT W, Dobrjansky A . Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989; 38(9):1165-74. DOI: 10.2337/diab.38.9.1165. View

18.

Gilling-Smith C, Willis D, BEARD R, Franks S . Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab. 1994; 79(4):1158-65. DOI: 10.1210/jcem.79.4.7962289. View

19.

Franks S . Polycystic ovary syndrome. N Engl J Med. 1995; 333(13):853-61. DOI: 10.1056/NEJM199509283331307. View

20.

Baarends W, Uilenbroek J, Kramer P, Hoogerbrugge J, van Leeuwen E, Themmen A . Anti-müllerian hormone and anti-müllerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth. Endocrinology. 1995; 136(11):4951-62. DOI: 10.1210/endo.136.11.7588229. View